Zhi Hong, PhD, is Executive Director, Chairman of the Board and CEO of Brii Biosciences which he founded in 2018.
Prior to starting Brii Biosciences, Zhi was Senior Vice President and Head of GlaxoSmithKline’s (GSK) Infectious Diseases Therapy Area Unit. He was widely credited as the key architect of GSK’s comeback and success in HIV and Infectious Diseases medicine discovery and development. Under his leadership, ViiV Healthcare’s (a joint venture between GSK, Pfizer, and Shionogi) HIV business was revitalized with the approval of Tivicay and Triumeq. Zhi was the champion of GSK’s effort in long-acting HIV treatment and prevention therapies resulting in the first approval of Cabenuva and Apretude, respectively.
Zhi is a public health advocate who has helped establish multiple public-private partnerships with the U.S./E.U. governments (DTRA, BARDA, NIH & IMI) and philanthropic organizations (Gates Foundation & Wellcome Trust). He helped to create GSK’s Institute for Infectious Diseases and Public Health in Beijing, China. Zhi started Ardea Biosciences (later acquired by AstraZeneca). He also held leadership positions at Valeant Pharmaceuticals and Schering-Plough Research Institute (now Merck).
Zhi has more than 25 years of experience in drug discovery and development and has brought more than 40 compounds into development, including many that have been approved and launched. He has served as a board member of ViiV Healthcare.